Effect of Colloid Versus Crystalloid on Coagulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to reduce bloodloss and need for transfusion to investigate the effect of colloid and crystalloid on coagulation assuming no difference between the groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

NCT02009033

Disorders of Coagulation

COMPLETED PHASE4

The Effect of Human Albumin on Coagulation Competence and Hemorrhage

NCT02270723

Hemorrhage; Complicating Delivery, Coagulation Defect

UNKNOWN PHASE4

Dilutional Coagulopathy in Patients Undergoing Elective Surgery

NCT00493272

Blood Coagulation Disorder

COMPLETED PHASE1/PHASE2

Impact of Balanced Crystalloid and Colloid Infusion on Haemostasis in Healthy Male Volunteers

NCT05148650

Perioperative Hemorrhage Dilutional Coagulopathy

UNKNOWN NA

Oral Administration of Tranexamic Acid in Anterior Cruciate Ligament Surgery Reduce Postoperative Haemarthrosis

NCT04855877

Hemorrhage Postoperative Anterior Cruciate Ligament Rupture Arthroscopy +1 more

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bloodloss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

crystalloid

Group Type ACTIVE_COMPARATOR

Ringer-lactate "SAD"

Intervention Type DRUG

Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.

colloid

Group Type PLACEBO_COMPARATOR

HES 130/04

Intervention Type DRUG

Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate "SAD".

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ringer-lactate "SAD"

Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.

Intervention Type DRUG

HES 130/04

Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate "SAD".

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ringer-laktat "SAD", B 05 BB 01, Amgros A/S. Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient more than 18 years old
* Indication for elective post-renal operation including cystectomy
* Patient without anticoagulative, acetylsalicylic acid or NSAID treatment for the last 5 days.

Exclusion Criteria

* Intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases
* Pregnant or nursing
* Allergic
* Disturbance in electrolytes
* Patient under committee
* Patient joining another trial interfering the actual trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No